These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
377 related articles for article (PubMed ID: 26756408)
1. Quantitative evaluation of correlation of dose and FDG-PET uptake value with clinical chest wall complications in patients with lung cancer treated with stereotactic body radiation therapy. Algan O; Confer M; Algan S; Matthiesen C; Herman T; Ahmad S; Ali I J Xray Sci Technol; 2015; 23(6):727-36. PubMed ID: 26756408 [TBL] [Abstract][Full Text] [Related]
2. Clinical prognostic factors and grading system for rib fracture following stereotactic body radiation therapy (SBRT) in patients with peripheral lung tumors. Kim SS; Song SY; Kwak J; Ahn SD; Kim JH; Lee JS; Kim WS; Kim SW; Choi EK Lung Cancer; 2013 Feb; 79(2):161-6. PubMed ID: 23182662 [TBL] [Abstract][Full Text] [Related]
3. Radiation-induced rib fracture after stereotactic body radiotherapy with a total dose of 54-56 Gy given in 9-7 fractions for patients with peripheral lung tumor: impact of maximum dose and fraction size. Aoki M; Sato M; Hirose K; Akimoto H; Kawaguchi H; Hatayama Y; Ono S; Takai Y Radiat Oncol; 2015 Apr; 10():99. PubMed ID: 25897487 [TBL] [Abstract][Full Text] [Related]
4. Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Dunlap NE; Cai J; Biedermann GB; Yang W; Benedict SH; Sheng K; Schefter TE; Kavanagh BD; Larner JM Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):796-801. PubMed ID: 19427740 [TBL] [Abstract][Full Text] [Related]
5. Chest wall toxicity after stereotactic body radiotherapy for malignant lesions of the lung and liver. Andolino DL; Forquer JA; Henderson MA; Barriger RB; Shapiro RH; Brabham JG; Johnstone PA; Cardenes HR; Fakiris AJ Int J Radiat Oncol Biol Phys; 2011 Jul; 80(3):692-7. PubMed ID: 21288656 [TBL] [Abstract][Full Text] [Related]
6. Predictors of chest wall toxicity after stereotactic ablative radiotherapy using real-time tumor tracking for lung tumors. Park Y; Kim HJ; Chang AR Radiat Oncol; 2017 Apr; 12(1):66. PubMed ID: 28381302 [TBL] [Abstract][Full Text] [Related]
7. Possibility of chest wall dose reduction using volumetric-modulated arc therapy (VMAT) in radiation-induced rib fracture cases: comparison with stereotactic body radiation therapy (SBRT). Murakami Y; Nakano M; Yoshida M; Hirashima H; Nakamura F; Fukunaga J; Hirose TA; Yoshioka Y; Oguchi M; Hirata H J Radiat Res; 2018 May; 59(3):327-332. PubMed ID: 29800456 [TBL] [Abstract][Full Text] [Related]
8. Characterization of Chest Wall Toxicity During Long-term Follow Up After Thoracic Stereotactic Body Radiation Therapy. Chipko C; Ojwang J; Gharai LR; Deng X; Mukhopadhyay N; Weiss E Pract Radiat Oncol; 2019 May; 9(3):e338-e346. PubMed ID: 30731275 [TBL] [Abstract][Full Text] [Related]
10. Incidence and risk factors for chest wall toxicity after risk-adapted stereotactic radiotherapy for early-stage lung cancer. Bongers EM; Haasbeek CJ; Lagerwaard FJ; Slotman BJ; Senan S J Thorac Oncol; 2011 Dec; 6(12):2052-7. PubMed ID: 22052227 [TBL] [Abstract][Full Text] [Related]
11. Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy of non-small cell lung cancer: a dose- and volume-response analysis. Pettersson N; Nyman J; Johansson KA Radiother Oncol; 2009 Jun; 91(3):360-8. PubMed ID: 19410314 [TBL] [Abstract][Full Text] [Related]
12. Chest wall and rib irradiation and toxicities of early-stage lung cancer patients treated with CyberKnife stereotactic body radiotherapy. Podder T; Biswas T; Yao M; Zhang Y; Kim E; Ellis RJ; Lo SS; Machtay M Future Oncol; 2014 Dec; 10(15):2311-7. PubMed ID: 25525841 [TBL] [Abstract][Full Text] [Related]
13. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy. Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359 [TBL] [Abstract][Full Text] [Related]
14. Late chest wall toxicity after MammoSite breast brachytherapy. Brashears JH; Dragun AE; Jenrette JM Brachytherapy; 2009; 8(1):19-25. PubMed ID: 18955019 [TBL] [Abstract][Full Text] [Related]
15. Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings. Nakajima N; Sugawara Y; Kataoka M; Hamamoto Y; Ochi T; Sakai S; Takahashi T; Kajihara M; Teramoto N; Yamashita M; Mochizuki T Ann Nucl Med; 2013 Apr; 27(3):261-70. PubMed ID: 23299492 [TBL] [Abstract][Full Text] [Related]
16. Predicting chest wall pain from lung stereotactic body radiotherapy for different fractionation schemes. Woody NM; Videtic GM; Stephans KL; Djemil T; Kim Y; Xia P Int J Radiat Oncol Biol Phys; 2012 May; 83(1):427-34. PubMed ID: 22197087 [TBL] [Abstract][Full Text] [Related]
17. Rib fracture after stereotactic radiotherapy for primary lung cancer: prevalence, degree of clinical symptoms, and risk factors. Nambu A; Onishi H; Aoki S; Tominaga L; Kuriyama K; Araya M; Saito R; Maehata Y; Komiyama T; Marino K; Koshiishi T; Sawada E; Araki T BMC Cancer; 2013 Feb; 13():68. PubMed ID: 23391264 [TBL] [Abstract][Full Text] [Related]